This article was originally published in The Tan Sheet
Bayer is closer to completing its friendly takeover of Schering AG after Merck KgaA agreed to relinquish its 21.8% share June 14. As of June 13, Bayer reported ownership of 23.36% of Schering shares; a 75% stake is required. Despite dropping its bid in March, Merck had bought Schering stock to bulk up its share. In response, Bayer filed suit in Manhattan federal court June 13, but dropped the charge the next day...
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.